Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major depressive disorder (MDD).The primary…
- Trial name
- NCT04244253
- Testing
- OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily
- Where
- Japan
- Volunteers
- 273 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Depression
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00183677
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Depression
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
A clinical study to evaluate safety, tolerability and efficacy of oral administration of ganaxolone in women with postpartum depression
- Conditions
- Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms
- Trial name
- NCT03460756
- Testing
- Ganaxolone
- Where
- 33 sites in United States
- Volunteers
- 84 people
- Sponsor
- Marinus Pharmaceuticals
Major Depressive Disorder
Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries
This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).
- Trial name
- NCT01571453
- Testing
- Vortioxetine (Lu AA21004), Venlafaxine extended release
- Volunteers
- 437 people
- Sponsor
- H. Lundbeck A/S
Psychotic Depression, Severe Major Depression With Psychotic Features
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by…
- Conditions
- Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
- Trial name
- NCT00637494
- Testing
- mifepristone
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Major Depressive Disorder
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
- Trial name
- NCT03737474
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression
Major depressive disorder (MDD) is the leading cause of disability in the developed world and is associated with lost productivity, increased health care utilization, and mortality.
- Trial name
- NCT02176408
- Testing
- Behavioral Activation, Exercise Intervention, Stretching Intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston University Charles River Campus
Depressive Disorder, Major, Metabolic Syndrome X
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid…
- Trial name
- NCT00671515
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joseph Calabrese, MD
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.
- Trial name
- NCT00596817
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 639 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Dysthymia
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression
- Trial name
- NCT03761030
- Testing
- L-DOPA
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- New York State Psychiatric Institute
Major Depression, Bipolar I Disorder
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a…
- Conditions
- Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression
- Trial name
- Bio-K (NCT03156504)
- Testing
- Ketamine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Schizophrenia, Bipolar Disorder
Individualizing Incentives for Alcohol in the Severely Mentally Ill
The investigators will evaluate the efficacy of a 2 various contingency management (CM) interventions (High-Magnitude CM, Shaping CM) for treating heavy drinking among individuals with serious mental illness and alcohol…
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
- Trial name
- NCT03481049
- Testing
- Usual CM, High-Magnitude CM, Shaping CM
- Where
- 2 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Washington State University
Depressive Disorder, Major
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
- Trial name
- NCT03614156
- Testing
- Rapastinel
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 363 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Postpartum Depressive Disorder
Quetiapine in Postpartum Depression
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
- Trial name
- NCT00681668
- Testing
- Quetiapine
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Adjunctive Treatment of Major Depressive Disorder
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy
- Trial name
- NCT03968159
- Testing
- Pimavanserin
- Where
- 85 sites in United States, Finland and 7 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Major Depression, Irritable Bowel Syndrome
Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression
This study will evaluate the efficacy of duloxetine in reducing depressive symptoms, abdominal pain, and other symptoms of Irritable Bowel Syndrome (IRS) in a population of outpatients with Major Depressive Disorder MDD and…
- Trial name
- IBS-MDD (NCT01754493)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute